# 26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00463567** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 2059 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive
- COPD
- Lung Diseases, Obstructive

## Interventions

- **DRUG:** Indacaterol
- **DRUG:** Formoterol (12 µg b.i.d.)
- **DRUG:** Tiotropium (18 µg o.d.)
- **DRUG:** Placebo to Indacaterol
- **DRUG:** Placebo to Formoterol

## Key facts

- **NCT ID:** NCT00463567
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 2059 (ACTUAL)
- **Last updated:** 2011-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00463567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00463567, "26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00463567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*